Mission Impacts
Cumulus will use the funding to expand its portfolio of companies and help accelerate the way new cancer drugs are progressed from discovery, through clinical trials to patients.
About Cumulus
Cumulus was founded in 2017, establishing the first organisation in Europe with a unique business model focused on accelerating the development of new cancer treatments.
Its aim is to fast-track therapies for cancers that don’t respond well to existing treatments.
Key Information
Alignment to the United Nation's Sustainable Development Goals
Good Health and Well-being
Decent Work and Economic Growth
Industry, Innovation and Infrastructure
Key quote
Founder and CEO Dr Clare Wareing said: "Oncology remains a vast and important area of scientific and clinical research.
“The ultimate goal is to increase the success rates at the vital phase III end of clinical testing, which currently remains at below 50%.
“The support from the Scottish National Investment Bank means we can both support our existing companies, expand our portfolio and continue to develop the next generation of cancer therapies."
